Does Cigna Cover Prometrium?

What Is Prometrium and Why Is It Prescribed?

Prometrium is the brand-name formulation of micronized progesterone, a bioidentical progestogen derived from plant sources and chemically identical to the progesterone produced by human ovaries. The FDA approved Prometrium in two oral doses: 100 mg for endometrial protection when combined with conjugated estrogens in postmenopausal women, and 200 mg for secondary amenorrhea. [1]

Progesterone matters in hormone therapy because unopposed estrogen stimulates endometrial proliferation and raises the risk of endometrial hyperplasia. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial (N=875, JAMA 1995) found that women on conjugated estrogens alone had a 62% rate of endometrial hyperplasia over three years, compared with roughly 1% in women taking micronized progesterone 200 mg cyclically (P<0.001). [2] That single datum explains why Cigna and other payers treat Prometrium as medically necessary when estrogen therapy is part of the regimen.

Micronized progesterone also carries a tolerability advantage over synthetic progestins. The PEPI authors noted that micronized progesterone produced a more favorable HDL-cholesterol profile than medroxyprogesterone acetate. [2] Endocrinology guidelines from The Endocrine Society recognize oral micronized progesterone as a first-line progestogen option in postmenopausal HRT. [3]

Cigna Formulary Status for Prometrium

Most Cigna commercial plans classify Prometrium as a Tier 2 preferred brand or Tier 3 non-preferred brand drug, depending on the specific plan design. Tier placement matters because it sets your copay or coinsurance before prior authorization is even considered.

Cigna operates multiple formulary lists across its PPO, HMO, and Connect (narrow network) plans. The Open Access Plus formulary, one of the most common commercial designs, typically places brand Prometrium on Tier 3 with a requirement to use the generic first. Generic micronized progesterone 100 mg and 200 mg capsules became broadly available after 2019, and Cigna preferred-drug lists generally list the generic on Tier 1 or Tier 2. If your prescriber writes "Prometrium brand medically necessary" with a clinical justification, Cigna may cover the brand at the non-preferred tier rate rather than denying it outright.

Cigna Medicare Advantage plans follow a separate Part D formulary. Under Medicare Part D rules, plans must cover "all or substantially all" drugs in six protected classes, but progesterone is not in one of those protected classes. Coverage depends on the specific plan year formulary, which Cigna updates annually each October 1. Members should verify coverage at Cigna's online formulary tool or call the number on the back of their insurance card before filling a new prescription.

The FDA label for Prometrium remains the anchor for any formulary coverage decision. [1] Prescriptions written for off-label uses, such as progesterone supplementation in premenopausal women, sleep support, or weight management, face a higher denial rate because Cigna's clinical coverage policies align closely with labeled indications.

Prior Authorization Criteria for Prometrium on Cigna

Cigna requires prior authorization for Prometrium on most commercial and Medicare Advantage plans. The PA is rated moderate difficulty, meaning a well-documented chart note usually satisfies the criteria without a peer-to-peer call.

Typical documentation Cigna requests includes:

• Confirmed diagnosis of menopause or secondary amenorrhea (ICD-10: N95.1 for menopause, N91.0 or N91.1 for secondary amenorrhea)
• Active co-prescription of an estrogen product (estradiol patch, oral estradiol, conjugated estrogens) for endometrial protection indication
• Prescriber attestation that the patient has tried and failed, or cannot tolerate, generic micronized progesterone if brand Prometrium is requested specifically
• Relevant lab work (FSH, estradiol) confirming menopausal status where applicable

Cigna's PA process runs under its pharmacy benefit management arm. Prescribers can submit via CoverMyMeds, Cigna's provider portal, or by fax using the plan's prior authorization form. [4] The standard review window is 72 hours for non-urgent requests; urgent requests require a response within 24 hours under federal regulations governing Medicare Advantage and most state-regulated commercial plans. [5]

The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement states: "Micronized progesterone is preferred over synthetic progestins when possible because of its more favorable cardiovascular and breast safety profile." [6] Citing that guideline language directly in a PA request or appeal letter strengthens the clinical case for brand Prometrium when a prescriber judges the generic formulation inadequate for a specific patient.

Does Cigna Require Step Therapy Before Prometrium?

Some Cigna plan designs include a step therapy (also called "fail-first") requirement for Prometrium. Step therapy means the plan requires a trial of a lower-cost alternative before it will cover the requested drug.

For Prometrium, the step therapy agent is almost always medroxyprogesterone acetate (Provera or generic MPA), which costs under $15 per month at most pharmacies. Cigna may also count generic micronized progesterone as satisfying the step, since the molecule is identical to brand Prometrium.

Step therapy requirements have regulatory limits. Under the 21st Century Cures Act provisions applicable to Medicare Advantage, and under step therapy reform laws enacted in more than 30 states, a patient may request a step therapy exception when:

1. The required drug is contraindicated or likely to cause an adverse reaction in the patient.
2. The required drug is expected to be ineffective based on the patient's medical history.
3. The patient already tried and failed the required drug.
4. The required drug would delay necessary care.

Medroxyprogesterone acetate carries different metabolic and breast-tissue effects compared with micronized progesterone. The Women's Health Initiative (WHI) trial showed that the combination of conjugated estrogens plus MPA was associated with a statistically significant increase in breast cancer risk (hazard ratio 1.26 to 95% CI 1.00 to 1.59) at 5.2 years mean follow-up (N=16,608). [7] Micronized progesterone has not demonstrated the same signal in observational data. Prescribers can use this distinction to argue a step therapy exception on safety grounds when MPA is the required step agent. [8]

How to Appeal a Cigna Denial of Prometrium

A denial is not a final answer. Cigna operates a two-level internal appeal process followed by access to an external independent review organization (IRO).

Level 1 Internal Appeal. Submit within 180 days of the denial notice. Include the prescriber's letter of medical necessity, relevant clinical guidelines (NAMS 2022 [6], Endocrine Society guidelines [3]), and any supporting labs. Cigna must respond within 30 days for a standard pre-service appeal or 72 hours for an urgent appeal.

Level 2 Internal Appeal. If Level 1 is denied, request a Level 2 review. A different Cigna medical director, not involved in the first decision, conducts this review. Response timelines are the same as Level 1.

External IRO Review. If both internal levels are denied, federal law (under the ACA and ERISA for self-funded plans) and most state laws give you the right to an independent external review. The IRO decision is binding on Cigna for fully insured plans. For self-funded employer plans, the employer is the plan sponsor and IRO decisions may not be binding, but most employers follow them.

Peer-to-Peer Call. Before filing a formal appeal, the prescribing clinician can request a peer-to-peer call with the Cigna medical director who issued the denial. This call often resolves moderate-difficulty denials without entering the formal appeal pipeline. The prescriber calls Cigna's provider services line, references the denial case number, and requests the call within 24 to 48 hours of the denial date.

The American College of Obstetricians and Gynecologists (ACOG) maintains that insurance coverage restrictions on FDA-approved hormone therapy "interfere with evidence-based individualized patient care." [9] Quoting this position statement in an appeal letter provides external authority supporting the prescriber's clinical judgment.

What Formulary Tier Is Prometrium on Cigna, and What Will I Pay?

Out-of-pocket cost depends on three variables: formulary tier, your plan's cost-sharing structure, and whether you have met your deductible.

A typical Tier 2 placement means a $30 to $60 copay per 30-day supply after the deductible. A Tier 3 placement means $60 to $100 per 30-day supply, or 30% to 50% coinsurance on some high-deductible plans. Before the deductible is met, most Cigna plans require you to pay the plan's contracted rate for the drug, which is usually lower than the retail list price of $180 per month.

Generic micronized progesterone (Tier 1 or Tier 2) typically costs $10 to $30 per month with insurance on most Cigna plans. If Cigna covers only the generic, switching to the generic brings the cost down dramatically while delivering the same active molecule.

Cash-pay options are often cheaper than using insurance for Prometrium. GoodRx and similar discount programs can bring the brand price to approximately $45 per month at some pharmacies, and generic micronized progesterone can cost as low as $15 per month cash. If your Cigna copay is higher than the cash price, paying out of pocket may make sense, though paying cash means the purchase does not count toward your plan deductible.

The FDA provides publicly accessible drug information that can help patients understand what they are being prescribed and why the formulation matters. [1]

Can I Use the Manufacturer Savings Card with Cigna?

The Prometrium manufacturer savings card (from AbbVie) reduces the brand copay for commercially insured patients. As of 2025, the card lowers the out-of-pocket cost to as little as $15 per month for eligible patients. [10]

The card is not valid for patients covered by any government-funded program, including Medicare, Medicaid, TRICARE, or the VA. Cigna Medicare Advantage members cannot use the savings card. Fully commercial Cigna members can generally use it.

Using a manufacturer savings card with a commercial Cigna plan is legal and common. The savings card covers the gap between the insurance copay and the manufacturer-set patient price. The plan still pays its contracted amount for the drug, so using the card does not typically affect Cigna's payment or your claim record.

One practical note: some Cigna high-deductible health plan (HDHP) designs paired with a Health Savings Account (HSA) have restrictions on manufacturer coupons counting toward the deductible under IRS rules. Confirm with your HR benefits team whether using the coupon affects your HSA-compatible deductible accumulation. [11]

Does Cigna Cover Prometrium for Weight Loss?

No. Prometrium is not FDA-approved for weight loss, and Cigna will not cover it for that indication. [1] Progesterone does affect body composition and fat distribution to some degree, observational data show that menopausal hormonal changes contribute to central adiposity, but no randomized controlled trial has established oral progesterone as an effective weight-loss treatment meeting the FDA's efficacy threshold of at least 5% greater weight loss than placebo. [12]

Prescriptions written for weight loss or "metabolic support" without an FDA-approved ICD-10 diagnosis code will be denied by Cigna at the pharmacy. A prescriber who submits a PA citing weight loss as the primary indication faces near-certain denial and the appeal is unlikely to succeed.

Patients seeking medical weight management through a Cigna plan should ask their clinician about FDA-approved GLP-1 receptor agonists such as semaglutide 2.4 mg (Wegovy). The STEP-1 trial (N=1,961) showed 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001). [13] Cigna covers GLP-1 agents for obesity under separate medical necessity criteria.

Practical Steps to Get Prometrium Covered by Cigna

Starting with the right preparation cuts the time from prescription to covered fill.

First, confirm the formulary. Log into myCigna.com or call the pharmacy benefit number on your card. Search for "micronized progesterone" (the generic) and "Prometrium" (the brand) separately. Note the tier and whether PA is flagged.

Second, have your prescriber submit the PA before the prescription goes to the pharmacy. Submitting PA after a pharmacy rejection adds 24 to 72 hours and sometimes requires restarting the process.

Third, gather supporting documentation ahead of time: recent labs (FSH above 40 IU/L for confirmed menopause), the estrogen co-prescription, and a chart note documenting the indication. The Endocrine Society's clinical practice guideline on menopause management is a citable reference that Cigna reviewers recognize. [3]

Fourth, if the PA is denied, request the peer-to-peer call within 48 hours. Prescribers who call within that window have a higher reversal rate than those who go directly to the written appeal.

Fifth, if peer-to-peer fails, file the Level 1 internal appeal with the NAMS 2022 Position Statement [6] and the PEPI trial data [2] as exhibits. The endometrial safety data from PEPI remain the strongest clinical argument for why micronized progesterone specifically, rather than synthetic MPA, is medically necessary for certain patients.

A Cigna denial letter must include the clinical reason for denial and cite the specific coverage policy applied. Federal law under 29 CFR 2590.715-2719 requires this for plans subject to ERISA. If your denial letter lacks that specificity, that deficiency itself is grounds for a procedural appeal. [14]